Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound

Journal of Hepatology

Volumn 65, Issue 4, 2016, Pages 700-710

  Wang, Jie ^a   Shen, Tao ^a   Huang, Xiangbo ^a   Kumar, G Renuka ^b   Chen, Xiangmei ^a   Zeng, Zhenzhen ^a   Zhang, Ruiyang ^a   Chen, Ran ^a   Li, Tong ^a   Zhang, Tianying ^c   Yuan, Quan ^c   Li, Pao Chen ^b   Huang, Qi ^b   Colonno, Richard ^b   Jia, Jidong ^d   Hou, Jinlin ^e   McCrae, Malcolm A ^f   Gao, Zhiliang ^g   Ren, Hong ^h   Xia, Ningshao ^c   Zhuang, Hui ^a   Lu, Fengmin ^a   more..

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b Assembly Biosciences Inc R D Main Facility   (United States)

^c XIAMEN UNIVERSITY   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

^e SOUTHERN MEDICAL UNIVERSITY   (China)

^f INSTITUTE FOR ANIMAL HEALTH   (United Kingdom)

^g THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^h CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

HBV pgRNA virion; Hepatitis B virus; Nucleot(s)ide analogues therapy

Indexed keywords

DNA POLYMERASE; NUCLEOSIDE DERIVATIVE; NUCLEOTIDE DERIVATIVE; PREGENOME RNA; RNA; UNCLASSIFIED DRUG; VIRUS DNA; MACROGOL DERIVATIVE; NONIDET P-40; VIRUS RNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG WITHDRAWAL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REBOUND; REVERSE TRANSCRIPTION; SERUM; VIRION; VIRUS LIKE AGENT; ANIMAL; CHRONIC HEPATITIS B;

ANIMALS; DNA, VIRAL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MICE; POLYETHYLENE GLYCOLS; RNA, VIRAL;

EID: 84991619847     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.05.029     Document Type: Article

References (41)

1. [1] Ott, J.J., Stevens, G.A., Groeger, J., Wiersma, S.T., Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 30 (2012), 2212–2219.
2. [2] Mohd, H.K., Groeger, J., Flaxman, A.D., Wiersma, S.T., Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57 (2013), 1333–1342.
3. [3] Trepo, C., Chan, H.L., Lok, A., Hepatitis B virus infection. Lancet 384 (2014), 2053–2063.
4. [4] Ganem, D., Prince, A.M., Hepatitis B virus infection–natural history and clinical consequences. N Engl J Med 350 (2004), 1118–1129.
5. [5] Pan, C.Q., Zhang, J.X., Natural history and clinical consequences of hepatitis B virus infection. Int J Med Sci 2 (2005), 36–40.
6. [6] Schadler, S., Hildt, E., HBV life cycle: entry and morphogenesis. Viruses 1 (2009), 185–209.
7. [7] Kock, J., Theilmann, L., Galle, P., Schlicht, H.J., Hepatitis B virus nucleic acids associated with human peripheral blood mononuclear cells do not originate from replicating virus. Hepatology 23 (1996), 405–413.
8. [8] Su, Q., Wang, S.F., Chang, T.E., Breitkreutz, R., Hennig, H., Takegoshi, K., et al. Circulating hepatitis B virus nucleic acids in chronic infection: representation of differently polyadenylated viral transcripts during progression to nonreplicative stages. Clin Cancer Res 7 (2001), 2005–2015.
9. [9] Jansen, L., Kootstra, N.A., van Dort, K.A., Takkenberg, R.B., Reesink, H.W., Zaaijer, H.L., Hepatitis B virus pregenomic RNA is present in virions in plasma and is associated with a response to pegylated interferon alfa-2a and nucleos(t)ide analogues. J Infect Dis 213 (2016), 224–232.
10. [10] Tsuge, M., Murakami, E., Imamura, M., Abe, H., Miki, D., Hiraga, N., et al. Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients. J Gastroenterol 48 (2013), 1188–1204.
11. [11] Hatakeyama, T., Noguchi, C., Hiraga, N., Mori, N., Tsuge, M., Imamura, M., et al. Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine. Hepatology 45 (2007), 1179–1186.
12. [12] Rokuhara, A., Matsumoto, A., Tanaka, E., Umemura, T., Yoshizawa, K., Kimura, T., et al. Hepatitis B virus RNA is measurable in serum and can be a new marker for monitoring lamivudine therapy. J Gastroenterol 41 (2006), 785–790.
13. [13] Huang, Y.W., Takahashi, S., Tsuge, M., Chen, C.L., Wang, T.C., Abe, H., et al. On-treatment low serum HBV RNA level predicts initial virological response in chronic hepatitis B patients receiving nucleoside analogue therapy. Antivir Ther 20 (2015), 369–375.
14. [14] van Bommel, F., Bartens, A., Mysickova, A., Hofmann, J., Kruger, D.H., Berg, T., et al. Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors. Hepatology 61 (2015), 66–76.
15. [15] J. Lucifora Y. Xia, Reisinger, F., Zhang, K., Stadler, D., Cheng, X., et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 343 (2014), 1221–1228.
16. [16] Wang, J., Xu, Z.W., Liu, S., Zhang, R.Y., Ding, S.L., Xie, X.M., et al. Dual gRNAs guided CRISPR/Cas9 system inhibits hepatitis B virus replication. World J Gastroenterol 21 (2015), 9554–9565.
17. [17] Zoulim, F., Hepatitis B virus resistance to antiviral drugs: where are we going?. Liver Int 31 (2011), 111–116.
18. [18] Nakabayashi, H., Taketa, K., Miyano, K., Yamane, T., Sato, J., Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res 42 (1982), 3858–3863.
19. [19] Sells, M.A., Chen, M.L., Acs, G., Production of hepatitis B virus particles in HepG2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci U S A 84 (1987), 1005–1009.
20. [20] Ladner, S.K., Otto, M.J., Barker, C.S., Zaifert, K., Wang, G.H., Guo, J.T., et al. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. Antimicrob Agents Chemother 41 (1997), 1715–1720.
21. [21] H. Yan G.C. Zhong, Xu, G.W., He, W.H., Jing, Z.Y., Gao, Z.C., et al. Sodium tauocholated cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife, 1, 2012, e00049.
22. [22] M.H. Wu W.L. Ma C.L. Hsu, Chen, Y.L., Ou, J.H., Ryan, C.K., et al. Androgen receptor promotes hepatitis B virus-induced hepatocarcinogenesis through modulation of hepatitis B virus RNA transcription. Sci Transl Med, 2, 2010, 32ra35.
23. [23] Wang, X.Y., Wei, Z.M., Wu, G.Y., Wang, J.H., Zhang, Y.J., Li, J., et al. In vitro inhibition of HBV replication by a novel compound, GLS4, and its efficacy against adefovir-dipivoxil-resistant HBV mutations. Antivir Ther 17 (2012), 793–803.
24. [24] Chen, R.Y., Edwards, R., Shaw, T., Colledge, D., Delaney, W.T., Isom, H., et al. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. Hepatology 37 (2003), 27–35.
25. [25] Gripon, P., Diot, C., Guguen-Guillouzo, C., Reproducible high level infection of cultured adult human hepatocytes by hepatitis B virus: effect of polyethylene glycol on adsorption and penetration. Virology 192 (1993), 534–540.
26. [26] Glebe, D., Gerlich, W.H., Study of the endocytosis and intracellular localization of subviral particles of hepatitis B virus in primary hepatocytes. Methods Mol Med 96 (2004), 143–151.
27. [27] T.N. Bukong F. Momen-Heravi, Kodys, K., Bala, S., Szabo, G., Exosomes from hepatitis C infected patients transmit HCV infection and contain replication competent viral RNA in complex with Ago2-miR122-HSP90. PLoS Pathog, 10, 2014, e1004424.
28. [28] Chahar, H.S., Bao, X., Casola, A., Exosomes and their role in the life cycle and pathogenesis of RNA viruses. Viruses 7 (2015), 3204–3225.
29. [29] Wu, G., Liu, B., Zhang, Y., Li, J., Arzumanyan, A., Clayton, M.M., et al. Preclinical characterization of GLS4, an inhibitor of hepatitis B virus core particle assembly. Antimicrob Agents Chemother. 57 (2013), 5344–5354.
30. [30] Hu, J., Seeger, C., Hepadnavirus genome replication and persistence. Cold Spring Harb Perspect Med, 5, 2015, a21386.
31. [31] Wang, J.C., Nickens, D.G., Lentz, T.B., Loeb, D.D., Zlotnick, A., Encapsidated hepatitis B virus reverse transcriptase is poised on an ordered RNA lattice. Proc Natl Acad Sci U S A 111 (2014), 11329–11334.
32. [32] Gerelsaikhan, T., Tavis, J.E., Bruss, V., Hepatitis B virus nucleocapsid envelopment does not occur without genomic DNA synthesis. J Virol 70 (1996), 4269–4274.
33. [33] Roseman, A.M., Berriman, J.A., Wynne, S.A., Butler, P.J., Crowther, R.A., A structural model for maturation of the hepatitis B virus core. Proc Natl Acad Sci U S A 102 (2005), 15821–15826.
34. [34] Gerin, J.L., Ford, E.C., Purcell, R.H., Biochemical characterization of Australia antigen. Evidence for defective particles of hepatitis B virus. Am J Pathol 81 (1975), 651–668.
35. [35] Kaplan, P.M., Ford, E.C., Purcell, R.H., Gerin, J.L., Demonstration of subpopulations of Dane particles. J Virol 17 (1976), 885–893.
36. [36] Sakamoto, Y., Yamada, G., Mizuno, M., Nishihara, T., Kinoyama, S., Kobayashi, T., et al. Full and empty particles of hepatitis B virus in hepatocytes from patients with HBsAg-positive chronic active hepatitis. Lab Invest 48 (1983), 678–682.
37. [37] Ning, X., Nguyen, D., Mentzer, L., Adams, C., Lee, H., Ashley, R., et al. Secretion of genome-free hepatitis B virus-single strand blocking model for virion morphogenesis of para-retrovirus. PLoS Pathog, 7, 2011, e1002255.
38. [38] Luckenbaugh, L., Kitrinos, K.M., Delaney, W.T., Hu, J., Genome-free hepatitis B virion levels in patient sera as a potential marker to monitor response to antiviral therapy. J Viral Hepat 22 (2015), 561–570.
39. [39] Ren, S., Nassal, M., Hepatitis B virus (HBV) virion and covalently closed circular DNA formation in primary tupaia hepatocytes and human hepatoma cell lines upon HBV genome transduction with replication-defective adenovirus vectors. J Virol 75 (2001), 1104–1116.
40. [40] Littlejohn, M., Locarnini, S., Yuen, L., Origins and evolution of hepatitis B virus and hepatitis D virus. Cold Spring Harb Perspect Med, 6, 2016, a021360.
41. [41] Huang, C.R., Lo, S.J., Hepatitis D virus infection, replication and cross-talk with the hepatitis B virus. World J Gastroenterol 20 (2014), 14589–14597.